S&P 500   5,251.31 (+0.05%)
DOW   39,763.21 (+0.01%)
QQQ   444.35 (-0.11%)
AAPL   171.14 (-1.25%)
MSFT   420.29 (-0.27%)
META   486.02 (-1.59%)
GOOGL   150.58 (-0.19%)
AMZN   179.90 (+0.04%)
TSLA   177.35 (-1.38%)
NVDA   905.26 (+0.31%)
NIO   4.61 (-1.28%)
AMD   181.80 (+1.23%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.26 (+1.53%)
MU   118.03 (-0.93%)
CGC   9.83 (+2.93%)
GE   175.65 (-2.48%)
DIS   122.77 (+1.48%)
AMC   3.70 (-14.75%)
PFE   27.89 (+0.40%)
PYPL   67.61 (+1.56%)
XOM   115.72 (+0.65%)
S&P 500   5,251.31 (+0.05%)
DOW   39,763.21 (+0.01%)
QQQ   444.35 (-0.11%)
AAPL   171.14 (-1.25%)
MSFT   420.29 (-0.27%)
META   486.02 (-1.59%)
GOOGL   150.58 (-0.19%)
AMZN   179.90 (+0.04%)
TSLA   177.35 (-1.38%)
NVDA   905.26 (+0.31%)
NIO   4.61 (-1.28%)
AMD   181.80 (+1.23%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.26 (+1.53%)
MU   118.03 (-0.93%)
CGC   9.83 (+2.93%)
GE   175.65 (-2.48%)
DIS   122.77 (+1.48%)
AMC   3.70 (-14.75%)
PFE   27.89 (+0.40%)
PYPL   67.61 (+1.56%)
XOM   115.72 (+0.65%)
S&P 500   5,251.31 (+0.05%)
DOW   39,763.21 (+0.01%)
QQQ   444.35 (-0.11%)
AAPL   171.14 (-1.25%)
MSFT   420.29 (-0.27%)
META   486.02 (-1.59%)
GOOGL   150.58 (-0.19%)
AMZN   179.90 (+0.04%)
TSLA   177.35 (-1.38%)
NVDA   905.26 (+0.31%)
NIO   4.61 (-1.28%)
AMD   181.80 (+1.23%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.26 (+1.53%)
MU   118.03 (-0.93%)
CGC   9.83 (+2.93%)
GE   175.65 (-2.48%)
DIS   122.77 (+1.48%)
AMC   3.70 (-14.75%)
PFE   27.89 (+0.40%)
PYPL   67.61 (+1.56%)
XOM   115.72 (+0.65%)
S&P 500   5,251.31 (+0.05%)
DOW   39,763.21 (+0.01%)
QQQ   444.35 (-0.11%)
AAPL   171.14 (-1.25%)
MSFT   420.29 (-0.27%)
META   486.02 (-1.59%)
GOOGL   150.58 (-0.19%)
AMZN   179.90 (+0.04%)
TSLA   177.35 (-1.38%)
NVDA   905.26 (+0.31%)
NIO   4.61 (-1.28%)
AMD   181.80 (+1.23%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.26 (+1.53%)
MU   118.03 (-0.93%)
CGC   9.83 (+2.93%)
GE   175.65 (-2.48%)
DIS   122.77 (+1.48%)
AMC   3.70 (-14.75%)
PFE   27.89 (+0.40%)
PYPL   67.61 (+1.56%)
XOM   115.72 (+0.65%)
NASDAQ:RVNC

Revance Therapeutics (RVNC) Stock Price, News & Analysis

$4.92
-0.02 (-0.40%)
(As of 12:33 PM ET)
Today's Range
$4.86
$5.03
50-Day Range
$4.65
$7.14
52-Week Range
$4.57
$37.98
Volume
356,458 shs
Average Volume
1.83 million shs
Market Capitalization
$512.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.75

Revance Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
180.6% Upside
$13.75 Price Target
Short Interest
Healthy
10.43% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
0.93mentions of Revance Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$134,553 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.17) to ($1.13) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.83 out of 5 stars

Medical Sector

38th out of 939 stocks

Pharmaceutical Preparations Industry

17th out of 433 stocks

RVNC stock logo

About Revance Therapeutics Stock (NASDAQ:RVNC)

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

RVNC Stock Price History

RVNC Stock News Headlines

Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
RVNC Apr 2024 5.000 put
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Q4 2023 Revance Therapeutics Inc Earnings Call
Earnings Outlook For Revance Therapeutics
Revance to Participate in Upcoming Investor Conferences
Halozyme Therapeutics (HALO) Q4 Earnings Match Estimates
See More Headlines
Receive RVNC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RVNC
Employees
597
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.75
High Stock Price Target
$20.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+178.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

Net Income
$-323,990,000.00
Net Margins
-138.43%
Pretax Margin
-138.30%

Debt

Sales & Book Value

Annual Sales
$234.04 million
Book Value
($1.73) per share

Miscellaneous

Free Float
98,901,000
Market Cap
$514.85 million
Optionable
Optionable
Beta
1.09
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

RVNC Stock Analysis - Frequently Asked Questions

Should I buy or sell Revance Therapeutics stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RVNC shares.
View RVNC analyst ratings
or view top-rated stocks.

What is Revance Therapeutics' stock price target for 2024?

8 brokerages have issued 1 year price targets for Revance Therapeutics' stock. Their RVNC share price targets range from $9.00 to $20.00. On average, they predict the company's stock price to reach $13.75 in the next twelve months. This suggests a possible upside of 180.6% from the stock's current price.
View analysts price targets for RVNC
or view top-rated stocks among Wall Street analysts.

How have RVNC shares performed in 2024?

Revance Therapeutics' stock was trading at $8.79 at the beginning of 2024. Since then, RVNC shares have decreased by 44.3% and is now trading at $4.90.
View the best growth stocks for 2024 here
.

When is Revance Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our RVNC earnings forecast
.

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics, Inc. (NASDAQ:RVNC) posted its quarterly earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.17. The biopharmaceutical company earned $69.80 million during the quarter, compared to the consensus estimate of $64.02 million. Revance Therapeutics had a negative net margin of 138.43% and a negative trailing twelve-month return on equity of 903.28%.

What ETFs hold Revance Therapeutics' stock?

ETFs with the largest weight of Revance Therapeutics (NASDAQ:RVNC) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE).

What is Mark Foley's approval rating as Revance Therapeutics' CEO?

7 employees have rated Revance Therapeutics Chief Executive Officer Mark Foley on Glassdoor.com. Mark Foley has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Revance Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Myovant Sciences (MYOV), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Sangamo Therapeutics (SGMO).

Who are Revance Therapeutics' major shareholders?

Revance Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Capital World Investors (13.60%), Palo Alto Investors LP (5.96%), Vanguard Group Inc. (5.77%), Vanguard Group Inc. (5.75%), Rubric Capital Management LP (1.66%) and CIBC Asset Management Inc (1.31%). Insiders that own company stock include Angus C Russell, Aubrey Rankin, Carey Oconnor Kolaja, Dustin S Sjuts, Dwight Moxie, Mark J Foley and Tobin Schilke.
View institutional ownership trends
.

How do I buy shares of Revance Therapeutics?

Shares of RVNC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RVNC) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners